158 related articles for article (PubMed ID: 30916611)
1. Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping.
Liu J; Xu Z; Li Y; Dai S; Liu J; Pan J; Jiang Y
Mol Membr Biol; 2019 Dec; 35(1):1-8. PubMed ID: 30916611
[TBL] [Abstract][Full Text] [Related]
2. Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease.
Ma L; Yuan Y; Li J; Yu C; Zhao J
Int J Immunogenet; 2020 Dec; 47(6):539-545. PubMed ID: 32862511
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
4. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program.
Hernandez-Suarez DF; Tomassini-Fernandini JC; Cuevas A; Rosario-Berrios AN; Nuñez-Medina HJ; Padilla-Arroyo D; Rivera N; Liriano J; Vega-Roman RK; Renta JY; Melin K; Duconge J
Int J Environ Res Public Health; 2018 May; 15(6):. PubMed ID: 29848980
[No Abstract] [Full Text] [Related]
5. CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019.
Wang T; Zhao T; Bao S; Jia L; Feng J; Yu A; Sun L; Guo X; Li H; Yu L
Medicine (Baltimore); 2020 Jul; 99(29):e20582. PubMed ID: 32702814
[TBL] [Abstract][Full Text] [Related]
6. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients.
Zhuo ZL; Xian HP; Long Y; Liu C; Sun YY; Ma YT; Gao H; Zhao JZ; Zhao XT
Anatol J Cardiol; 2018 Feb; 19(2):123-129. PubMed ID: 29350207
[TBL] [Abstract][Full Text] [Related]
8. The effects of polymorphisms in CYP2C19, ATP-binding cassette transporter B1, and paraoxonase-1 on clopidogrel treatment of Uygur patients following percutaneous coronary intervention.
Wang T; Li H; Wang F; Sun L; Yu L
Eur J Clin Pharmacol; 2021 Nov; 77(11):1679-1686. PubMed ID: 34164723
[TBL] [Abstract][Full Text] [Related]
9. Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Galeazzi R; Olivieri F; Spazzafumo L; Rose G; Montesanto A; Giovagnetti S; Cecchini S; Malatesta G; Di Pillo R; Antonicelli R
Drugs Aging; 2018 Jul; 35(7):649-656. PubMed ID: 29936693
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
11. [Association of
Zhang T; Rao QM; He YY; Cai JT; Liu HY; Lin YL
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Mar; 56(3):287-294. PubMed ID: 35381649
[No Abstract] [Full Text] [Related]
12. Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Pan Y; Chen W; Wang Y; Li H; Johnston SC; Simon T; Zhao X; Liu L; Wang D; Meng X; Wang Y;
JAMA Neurol; 2019 May; 76(5):552-560. PubMed ID: 30742211
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X
J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.
Santos PC; Soares RA; Santos DB; Nascimento RM; Coelho GL; Nicolau JC; Mill JG; Krieger JE; Pereira AC
BMC Med Genet; 2011 Jan; 12():13. PubMed ID: 21247447
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention.
Saiz-Rodríguez M; Belmonte C; Caniego JL; Koller D; Zubiaur P; Bárcena E; Romero-Palacián D; Eugene AR; Ochoa D; Abad-Santos F
Clin Ther; 2019 Jun; 41(6):1199-1212.e2. PubMed ID: 31128980
[TBL] [Abstract][Full Text] [Related]
16. CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
Hou X; Han W; Gan Q; Liu Y; Fang W
J Clin Lab Anal; 2018 Jun; 32(5):e22369. PubMed ID: 29397568
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
Su Q; Li J; Tang Z; Yang S; Xing G; Liu T; Peng H
Med Sci Monit; 2019 Sep; 25():7138-7148. PubMed ID: 31543510
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
[TBL] [Abstract][Full Text] [Related]
20. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
